Table 2.
Patients with clinical or radiological recurrence among the evaluable population.
| Patient ID | 19 | 22 | 7 | 3 | 14 | 13 | 10 |
| Primary | Larynx | Oral Cavity | OPC | OPC | OPC | Larynx | OPC |
| Stage | III | III | III | III | III | III | III |
| p16 | Negative | Negative | Positive | Positive | Positive | Negative | Positive |
| Treatment | RT | Surgery + RT | CRT | CRT | CRT | CRT | CRT |
| Time to recurrence (days) | 203 | 228 | 356 | 605 | 638 | 653 | 731 |
| Site of recurrence | Local | Local | Distant (lung) | Distant (lung) | Local and distant (lung) | Local | Local |
| Treatment of recurrence | Salvage surgery | Systemic therapy | None | Lung SBRT | Systemic treatment | Salvage surgery | Systemic therapy |
| Alive | No | No | No | Yes | Yes | Yes | Yes |
| RaDaR | FU2:+ | Not performed |
FU1:− FU2: Indet. |
FU1:− |
FU1:− FU2:− |
FU1:− FU2:− |
FU1:− FU2:− |
| CAPP-seq | FU2:− | Not evaluable |
FU1:− FU2:− |
FU1:+ |
FU1:+ FU2:+ |
FU1:− FU2:− |
FU1:− FU2:− |
| HPV-seq | FU2: NA | FU1/2: NA |
FU1:+ FU2:+ |
FU1:+ |
FU1:− FU2:+ |
FU1/2: NA |
FU1:− FU2:+ |
| dPCR (HPV) | FU2: NA | FU1/2: NA |
FU1:− FU2:− |
FU1:+ |
FU1:+ FU2:+ |
FU1/2: NA |
FU1:− FU2:− |
Main characteristics at baseline, recurrence and assays available for each patient and follow-up timepoints (bold represents detectable).
CRT chemoradiation, dPCR digital PCR, FU follow-up, Indet indeterminate, NA non-applicable, OPC oropharynx, RT Radiation.